Spero Therapeutics Announces Director Changes and Shareholder Votes
Ticker: SPRO · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1701108
| Field | Detail |
|---|---|
| Company | Spero Therapeutics, Inc. (SPRO) |
| Form Type | 8-K |
| Filed Date | Jun 3, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, governance, shareholder-vote
TL;DR
Spero Therapeutics swapped a director, elected a new one, and held a shareholder vote on May 29th.
AI Summary
On May 29, 2024, Spero Therapeutics, Inc. announced the departure of Director David E. Melnick and the election of new Director Jonathan J. Lim. The company also reported on the appointment of certain officers and compensatory arrangements. Additionally, Spero Therapeutics held a meeting where matters were submitted to a vote of security holders.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Director changes and executive compensation adjustments can indicate internal shifts that may affect the company's future direction and performance.
Key Players & Entities
- Spero Therapeutics, Inc. (company) — Registrant
- David E. Melnick (person) — Departing Director
- Jonathan J. Lim (person) — Newly Elected Director
- May 29, 2024 (date) — Date of earliest event reported
FAQ
Who has departed from the Board of Directors at Spero Therapeutics?
David E. Melnick has departed from the Board of Directors.
Who has been elected as a new Director at Spero Therapeutics?
Jonathan J. Lim has been elected as a new Director.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 29, 2024.
What other items are covered in this 8-K filing besides director changes?
This filing also covers the appointment of certain officers, compensatory arrangements of certain officers, and the submission of matters to a vote of security holders.
In which state was Spero Therapeutics, Inc. incorporated?
Spero Therapeutics, Inc. was incorporated in Delaware.
Filing Stats: 753 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-06-03 16:15:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SPRO The Nasdaq Global Se
Filing Documents
- d842476d8k.htm (8-K) — 40KB
- d842476dex101.htm (EX-10.1) — 107KB
- 0001193125-24-153034.txt ( ) — 292KB
- spro-20240529.xsd (EX-101.SCH) — 3KB
- spro-20240529_lab.xml (EX-101.LAB) — 18KB
- spro-20240529_pre.xml (EX-101.PRE) — 11KB
- d842476d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits (d)Exhibits Exhibit Number Description 10.1# Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). # Management contract or compensatory plan. 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 3, 2024 SPERO THERAPEUTICS, INC. By: /s/ Esther Rajavelu Esther Rajavelu Chief Financial Officer and Chief Business Officer 4